Cargando…
Vitamin D Receptor Agonists Target CXCL10: New Therapeutic Tools for Resolution of Inflammation
Understanding the many biological extraskeletal actions of vitamin D has increased in the past decades. Indeed, vitamin D and analogue molecules, besides the classical actions on bone metabolism, exert several beneficial effects on metabolic homeostasis, heart-cardiovascular, brain, and muscle physi...
Autores principales: | Scolletta, Sabino, Colletti, Marta, Di Luigi, Luigi, Crescioli, Clara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3652186/ https://www.ncbi.nlm.nih.gov/pubmed/23690671 http://dx.doi.org/10.1155/2013/876319 |
Ejemplares similares
-
Phosphodiesterase Type 5 Inhibitor Sildenafil Decreases the Proinflammatory Chemokine CXCL10 in Human Cardiomyocytes and in Subjects with Diabetic Cardiomyopathy
por: Di Luigi, Luigi, et al.
Publicado: (2016) -
The Vitamin D Receptor Agonist BXL-01-0029 as a Potential New Pharmacological Tool for the Treatment of Inflammatory Myopathies
por: Di Luigi, Luigi, et al.
Publicado: (2013) -
Muscle Damage in Systemic Sclerosis and CXCL10: The Potential Therapeutic Role of PDE5 Inhibition
por: Corinaldesi, Clarissa, et al.
Publicado: (2021) -
The Prostacyclin Analogue Iloprost Modulates CXCL10 in Systemic Sclerosis
por: Colasanti, Tania, et al.
Publicado: (2022) -
Vitamin D Receptor Agonists: Suitable Candidates as Novel Therapeutic Options in Autoimmune Inflammatory Myopathy
por: Crescioli, Clara
Publicado: (2014)